Compare PTCT & ACLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | ACLS |
|---|---|---|
| Founded | 1998 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.8B |
| IPO Year | 2006 | 2000 |
| Metric | PTCT | ACLS |
|---|---|---|
| Price | $82.28 | $145.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 4 |
| Target Price | $80.65 | ★ $101.50 |
| AVG Volume (30 Days) | ★ 2.2M | 660.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 264.48 | N/A |
| EPS | N/A | ★ 0.30 |
| Revenue | $264,734,000.00 | ★ $839,048,000.00 |
| Revenue This Year | N/A | $1.93 |
| Revenue Next Year | $17.70 | $7.91 |
| P/E Ratio | ★ N/A | $481.00 |
| Revenue Growth | ★ 36.19 | N/A |
| 52 Week Low | $43.18 | $65.64 |
| 52 Week High | $87.50 | $193.78 |
| Indicator | PTCT | ACLS |
|---|---|---|
| Relative Strength Index (RSI) | 65.15 | 40.90 |
| Support Level | $73.41 | $137.70 |
| Resistance Level | $87.27 | $147.94 |
| Average True Range (ATR) | 3.11 | 12.40 |
| MACD | 0.22 | -2.86 |
| Stochastic Oscillator | 75.57 | 5.43 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.